A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice

Journal of Immunology

Volumn 189, Issue 5, 2012, Pages 2318-2325

  Poe, Jonathan C ^a   Minard Colin, Veronique ^a   Kountikov, Evgueni I ^a   Haas, Karen M ^a   Tedder, Thomas F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CYCLIN D2; MYC PROTEIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL SURFACE; CELL TRANSFORMATION; CONTROLLED STUDY; LIFESPAN; LYMPHOCYTE COUNT; LYMPHOID TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL;

ANIMALS; ANTIGENS, CD19; B-LYMPHOCYTE SUBSETS; DISEASE PROGRESSION; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 84865433574     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201000     Document Type: Article

References (51)

1. Fujimoto, M., J. C. Poe, M. Inaoki, and T. F. Tedder. 1998. CD19 regulates B lymphocyte responses to transmembrane signals. Semin. Immunol. 10: 267-277.
2. Matsumoto, A. K., J. Kopicky-Burd, R. H. Carter, D. A. Tuveson, T. F. Tedder, and D. T. Fearon. 1991. Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J. Exp. Med. 173: 55-64.
3. Bradbury, L. E., G. S. Kansas, S. Levy, R. L. Evans, and T. F. Tedder. 1992. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J. Immunol. 149: 2841-2850.
4. Bradbury, L. E., V. S. Goldmacher, and T. F. Tedder. 1993. The CD19 signal transduction complex of B lymphocytes: deletion of the CD19 cytoplasmic domain alters signal transduction but not complex formation with TAPA-1 and Leu 13. J. Immunol. 151: 2915-2927.
5. Sato, S., A. S. Miller, M. C. Howard, and T. F. Tedder. 1997. Regulation of B lymphocyte development and activation by the CD19/CD21/CD81/Leu 13 complex requires the cytoplasmic domain of CD19. J. Immunol. 159: 3278-3287.
6. Carter, R. H., and D. T. Fearon. 1992. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256: 105-107.
7. Haas, K. M., and T. F. Tedder. 2005. Role of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunity. Adv. Exp. Med. Biol. 560: 125-139.
8. Anderson, K. C., M. P. Bates, B. L. Slaughenhoupt, G. S. Pinkus, S. F. Schlossman, and L. M. Nadler. 1984. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63: 1424-1433.
9. Nadler, L. M., K. C. Anderson, G. Marti, M. Bates, E. Park, J. F. Daley, and S. F. Schlossman. 1983. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J. Immunol. 131: 244-250.
10. Loken, M. R., V. O. Shah, K. L. Dattilio, and C. I. Civin. 1987. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood 70: 1316-1324.
11. Uckun, F. M., W. Jaszcz, J. L. Ambrus, A. S. Fauci, K. Gajl-Peczalska, C. W. Song, M. R. Wick, D. E. Myers, K. Waddick, and J. A. Ledbetter. 1988. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71: 13-29.
12. Sato, S., D. A. Steeber, P. J. Jansen, and T. F. Tedder. 1997. CD19 expression levels regulate B lymphocyte development: human CD19 restores normal function in mice lacking endogenous CD19. J. Immunol. 158: 4662-4669.
13. Sato, S., N. Ono, D. A. Steeber, D. S. Pisetsky, and T. F. Tedder. 1996. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J. Immunol. 157: 4371-4378.
14. Krop, I., A. L. Shaffer, D. T. Fearon, and M. S. Schlissel. 1996. The signaling activity of murine CD19 is regulated during cell development. J. Immunol. 157: 48-56.
15. Boyd, A. W., K. C. Anderson, A. S. Freedman, D. C. Fisher, B. Slaughenhoupt, S. F. Schlossman, and L. M. Nadler. 1985. Studies of in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody. J. Immunol. 134: 1516-1523.
16. van Zelm, M. C., I. Reisli, M. van der Burg, D. Castaño, C. J. van Noesel, M. J. van Tol, C. Woellner, B. Grimbacher, P. J. Patiño, J. J. van Dongen, and J. L. Franco. 2006. An antibody-deficiency syndrome due to mutations in the CD19 gene. N. Engl. J. Med. 354: 1901-1912.
17. Engel, P., L.-J. Zhou, D. C. Ord, S. Sato, B. Koller, and T. F. Tedder. 1995. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3: 39-50.
18. Rickert, R. C., K. Rajewsky, and J. Roes. 1995. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 376: 352-355.
19. Poe, J. C., M. Hasegawa, and T. F. Tedder. 2001. CD19, CD21, and CD22: multifaceted response regulators of B lymphocyte signal transduction. Int. Rev. Immunol. 20: 739-762.
20. Sato, S., D. A. Steeber, and T. F. Tedder. 1995. The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation. Proc. Natl. Acad. Sci. USA 92: 11558-11562.
21. Sato, S., M. Hasegawa, M. Fujimoto, T. F. Tedder, and K. Takehara. 2000. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J. Immunol. 165: 6635-6643.
22. Rui, L., R. Schmitz, M. Ceribelli, and L. M. Staudt. 2011. Malignant pirates of the immune system. Nat. Immunol. 12: 933-940.
23. Scheuermann, R. H., and E. Racila. 1995. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk. Lymphoma 18: 385-397.
24. Adams, J. M., A. W. Harris, C. A. Pinkert, L. M. Corcoran, W. S. Alexander, S. Cory, R. D. Palmiter, and R. L. Brinster. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533-538.
25. Harris, A. W., C. A. Pinkert, M. Crawford, W. Y. Langdon, R. L. Brinster, and J. M. Adams. 1988. The E mu-myc transgenic mouse: a model for high-incidence spontaneous lymphoma and leukemia of early B cells. J. Exp. Med. 167: 353-371.
26. Langdon, W. Y., A. W. Harris, S. Cory, and J. M. Adams. 1986. The c-myc oncogene perturbs B lymphocyte development in E-μ-myc transgenic mice. Cell 47: 11-18.
27. Fujimoto, M., J. C. Poe, P. J. Jansen, S. Sato, and T. F. Tedder. 1999. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J. Immunol. 162: 7088-7094.
28. Fujimoto, M., Y. Fujimoto, J. C. Poe, P. J. Jansen, C. A. Lowell, A. L. DeFranco, and T. F. Tedder. 2000. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 13: 47-57.
29. Sato, S., P. J. Jansen, and T. F. Tedder. 1997. CD19 and CD22 expression reciprocally regulates tyrosine phosphorylation of Vav protein during B lymphocyte signaling. Proc. Natl. Acad. Sci. USA 94: 13158-13162.
30. Tooze, R. M., G. M. Doody, and D. T. Fearon. 1997. Counterregulation by the coreceptors CD19 and CD22 of MAP kinase activation by membrane immunoglobulin. Immunity 7: 59-67.
31. Li, X., and R. H. Carter. 1998. Convergence of CD19 and B cell antigen receptor signals at MEK1 in the ERK2 activation cascade. J. Immunol. 161: 5901-5908.
32. O'Rourke, L. M., R. Tooze, M. Turner, D. M. Sandoval, R. H. Carter, V. L. J. Tybulewicz, and D. T. Fearon. 1998. CD19 as a membrane-anchored adaptor protein of B lymphocytes: costimulation of lipid and protein kinases by recruitment of Vav. Immunity 8: 635-645.
33. Chalupny, N. J., S. B. Kanner, G. L. Schieven, S. F. Wee, L. K. Gilliland, A. Aruffo, and J. A. Ledbetter. 1993. Tyrosine phosphorylation of CD19 in pre-B and mature B cells. EMBO J. 12: 2691-2696.
34. Fujimoto, M., A. P. Bradney, J. C. Poe, D. A. Steeber, and T. F. Tedder. 1999. Modulation of B lymphocyte antigen receptor signal transduction by a CD19/ CD22 regulatory loop. Immunity 11: 191-200.
35. Uckun, F. M., A. L. Burkhardt, L. Jarvis, X. Jun, B. Stealey, I. Dibirdik, D. E. Myers, L. Tuel-Ahlgren, and J. B. Bolen. 1993. Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. J. Biol. Chem. 268: 21172-21184.
36. Kozmik, Z., S. Wang, P. Dörfler, B. Adams, and M. Busslinger. 1992. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol. Cell. Biol. 12: 2662-2672.
37. Nutt, S. L., P. Urbánek, A. Rolink, and M. Busslinger. 1997. Essential functions of Pax5 (BSAP) in pro-B cell development: difference between fetal and adult B lymphopoiesis and reduced V-to-DJ recombination at the IgH locus. Genes Dev. 11: 476-491.
38. Sears, R., G. Leone, J. DeGregori, and J. R. Nevins. 1999. Ras enhances Myc protein stability. Mol. Cell 3: 169-179.
39. Sears, R., F. Nuckolls, E. Haura, Y. Taya, K. Tamai, and J. R. Nevins. 2000. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14: 2501-2514.
40. Chung, E. Y., J. N. Psathas, D. Yu, Y. Li, M. J. Weiss, and A. Thomas- Tikhonenko. 2012. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J. Clin. Invest. 122: 2257-2266.
41. Hemann, M. T., A. Bric, J. Teruya-Feldstein, A. Herbst, J. A. Nilsson, C. Cordon-Cardo, J. L. Cleveland, W. P. Tansey, and S. W. Lowe. 2005. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436: 807-811.
42. Mohamedali, A., I. Soeiro, N. C. Lea, J. Glassford, L. Banerji, G. J. Mufti, E. W. Lam, and N. S. Thomas. 2003. Cyclin D2 controls B cell progenitor numbers. J. Leukoc. Biol. 74: 1139-1143.
43. Tuveson, D. A., R. H. Carter, S. P. Soltoff, and D. T. Fearon. 1993. CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science 260: 986-989.
44. Wang, Y., and R. H. Carter. 2005. CD19 regulates B cell maturation, proliferation, and positive selection in the FDC zone of murine splenic germinal centers. Immunity 22: 749-761.
45. Piatelli, M. J., C. Doughty, and T. C. Chiles. 2002. Requirement for a hsp90 chaperone-dependent MEK1/2-ERK pathway for B cell antigen receptor-induced cyclin D2 expression in mature B lymphocytes. J. Biol. Chem. 277: 12144-12150.
46. Pajic, A., D. Spitkovsky, B. Christoph, B. Kempkes, M. Schuhmacher, M. S. Staege, M. Brielmeier, J. Ellwart, F. Kohlhuber, G. W. Bornkamm, et al. 2000. Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int. J. Cancer 87: 787-793.
47. Bouchard, C., O. Dittrich, A. Kiermaier, K. Dohmann, A. Menkel, M. Eilers, and B. Lüscher. 2001. Regulation of cyclin D2 gene expression by the Myc/Max/ Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev. 15: 2042-2047.
48. Lam, E. W., J. Glassford, L. Banerji, N. S. Thomas, P. Sicinski, and G. G. Klaus. 2000. Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40. J. Biol. Chem. 275: 3479-3484.
49. Pokrovskaja, K., B. Ehlin-Henriksson, J. Bartkova, J. Bartek, R. Scuderi, L. Szekely, K. G. Wiman, and G. Klein. 1996. Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines. Cell Growth Differ. 7: 1723-1732.
50. Haas, K. M., J. C. Poe, D. A. Steeber, and T. F. Tedder. 2005. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 23: 7-18.
51. + phenotype controls T cell-dependent inflammatory responses. Immunity 28: 639-650.